New hope to save hearing for cancer patients
NCT ID NCT07218913
Summary
This early-stage trial is testing whether adding a drug called Pedmark to standard chemotherapy can reduce hearing damage in men with metastatic testicular cancer. The study will compare hearing outcomes between two groups: one receiving chemotherapy alone and one receiving chemotherapy plus Pedmark. Researchers hope to find a way to protect patients' hearing while still effectively treating their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEARING LOSS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.